News & Events



news_id: 96

ForteBio Sold!

Pall Corporation, specialized in filtration, separation and purification techniques, has entered into a definitive merger agreement for the acquisition of ForteBio, a provider of advanced analytical systems to advance discovery and development of biotech drugs.

ForteBio will provide a range of innovative, label-free protein analysis instruments that will extend Pall's capabilities in the biopharmaceuticals process monitoring market and in the protein research market.

ForteBio's portfolio of analytical solutions will enable researchers to measure proteins in real time without the aid of fluorescent, radio or calorimetric labels or markers that can contaminate samples.

Through this, characterization of drug candidates becomes easier and faster there by enabling an improvement in the process development and speed time to market.

The deal is expected to close by February 2012 and the financial terms of the deal have not been revealed.

ForteBio was founded by Dr. Hong Tan. Dr. Tan was graduated from Xi'an University as an Electric Engineer. He recieved PhD in Electric Engineering from Auburn University and recently MBA from Cheung Kong Graguate School of Business.

Dr. Tan started his first venture, Wave Cross, in 2000 and then started ForteBio in 2001. Dr. Tan is currently the CEO of ET Healthcare corp.

ForteBio Sold!

SABPA Seminar: Seizing Opportunities in US and China

First Chinese scientist to win Lasker Award

Pfizer’s XALKORI® (crizotinib) Approved by FDA

上海交大认定人耳鼠技术真实

著名学者饶毅落选中科院院士

Novartis on Shanghai Stock Exchange?

中国最具投资价值城市和园区

王国强:中药的发展要坚持中国标准

CAS Inst of Biophysics and Univ. Penn forms collaborative brain mapping center

US-China Biopharm Congress Philadelphia 2011 / SAPA-GP 9th Annual Conference

Burrill: Huge Payoff of Genomic Project

Page: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |